Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure

Background The impact of skeletal muscle size, quantified using simple noninvasive images routinely obtained during cardiac magnetic resonance imaging studies on mortality in the heart failure (HF) population is currently unknown. Methods and Results We prospectively enrolled 567 subjects without HF (n=364), with HF with reduced ejection fraction (n=111), or with HF with preserved ejection fraction (n=92), who underwent a cardiac magnetic resonance imaging. Skeletal muscle cross‐sectional area was assessed with manual tracing of major thoracic muscle groups on axial chest magnetic resonance images. Factor analysis was used to identify a latent factor underlying the shared variability in thoracic muscle cross‐sectional area. Cox regression was used to assess the relationship between these measurements and all‐cause mortality (median follow up, 36.4 months). A higher overall thoracic muscle area factor assessed with principal component analysis was independently associated with lower mortality (standardized hazard ratio, 0.51; P<0.0001). The thoracic muscle area factor was predictive of death in subjects with HF with preserved ejection fraction, HF with reduced ejection fraction, and those without HF. Among all muscle groups, the pectoralis major cross‐sectional area was the most representative of overall muscle area and was also the most robust predictor of death. A higher pectoralis major cross‐sectional area predicted a lower mortality (standardized hazard ratio, 0.49; P<0.0001), which persisted after adjustment for various confounders (standardized hazard ratio, 0.55; P=0.0017). Conclusions Axial muscle size, and in particular smaller size of the pectoralis major, is independently associated with higher risk of mortality in patients with and without HF. Further work should clarify the role of muscle wasting as a therapeutic target in patients with HF.

[1]  R. John,et al.  Preoperative Pectoralis Muscle Quantity and Attenuation by Computed Tomography Are Novel and Powerful Predictors of Mortality After Left Ventricular Assist Device Implantation , 2017, Circulation. Heart failure.

[2]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[3]  A. Bierhals,et al.  Usefulness of Psoas Muscle Area Determined by Computed Tomography to Predict Mortality or Prolonged Length of Hospital Stay in Patients Undergoing Left Ventricular Assist Device Implantation. , 2016, The American journal of cardiology.

[4]  F. Landi,et al.  Sarcopenia in heart failure: mechanisms and therapeutic strategies , 2016, Journal of geriatric cardiology : JGC.

[5]  R. Arena,et al.  Bulking Up Skeletal Muscle to Improve Heart Failure Prognosis. , 2016, JACC. Heart failure.

[6]  K. Kamiya,et al.  Complementary Role of Arm Circumference to Body Mass Index in Risk Stratification in Heart Failure. , 2016, JACC. Heart failure.

[7]  F. Flachskampf,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[8]  M. Haykowsky,et al.  High-intensity interval training vs. moderate-intensity continuous exercise training in heart failure with preserved ejection fraction: a pilot study. , 2015, Journal of applied physiology.

[9]  A. Jette,et al.  PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH TASK FORCE. , 2015, The Journal of frailty & aging.

[10]  J. Shuster,et al.  Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis , 2014, BMC Medicine.

[11]  S. Bartels,et al.  Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III , 2014, European Journal of Clinical Nutrition.

[12]  G. Azhar,et al.  New Approaches to Treating Cardiac Cachexia in the Older Patient , 2013, Current Cardiovascular Risk Reports.

[13]  W. Hundley,et al.  Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. , 2013, Journal of the American College of Cardiology.

[14]  G. Onder,et al.  Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. , 2013, Age and ageing.

[15]  S. Anker,et al.  Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). , 2013, European heart journal.

[16]  S. Blair,et al.  Effects of Muscular Strength on Cardiovascular Risk Factors and Prognosis , 2012, Journal of cardiopulmonary rehabilitation and prevention.

[17]  U. Wisløff,et al.  Exercise Training Prevents Oxidative Stress and Ubiquitin-Proteasome System Overactivity and Reverse Skeletal Muscle Atrophy in Heart Failure , 2012, PloS one.

[18]  J. Little,et al.  Exercise and nutritional interventions for improving aging muscle health , 2012, Endocrine.

[19]  F. Iellamo,et al.  Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. , 2010, Journal of the American College of Cardiology.

[20]  S. Anker,et al.  The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study , 2010, Journal of cachexia, sarcopenia and muscle.

[21]  Douglas E Schaubel,et al.  Sarcopenia and mortality after liver transplantation. , 2010, Journal of the American College of Surgeons.

[22]  F. Iellamo,et al.  Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. , 2009, Journal of the American College of Cardiology.

[23]  C. Opasich,et al.  Adequate energy‐protein intake is not enough to improve nutritional and metabolic status in muscle‐depleted patients with chronic heart failure , 2008, European journal of heart failure.

[24]  M. Cesari,et al.  Target population for clinical trials on sarcopenia , 2008, The journal of nutrition, health & aging.

[25]  P. Stenvinkel,et al.  Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. , 2007, The American journal of clinical nutrition.

[26]  Robert Ross,et al.  Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability , 2002, Journal of the American Geriatrics Society.

[27]  Jeffrey M. Hausdorff,et al.  Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. , 2001, Journal of applied physiology.

[28]  C. Baird The pilot study. , 2000, Orthopedic nursing.

[29]  R. Lenkinski,et al.  Contribution of Skeletal Muscle Atrophy to Exercise Intolerance and Altered Muscle Metabolism in Heart Failure , 1992, Circulation.

[30]  D. Houston,et al.  Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. , 2008, The American journal of clinical nutrition.